Trichostatin A, lead compound for development of antifibrogenic drugs

被引:0
|
作者
Rombouts, K [1 ]
Niki, T [1 ]
Wielant, A [1 ]
Hellemans, K [1 ]
Geerts, A [1 ]
机构
[1] Free Univ Brussels, Lab Mol Liver Cell Biol, B-1090 Brussels, Belgium
关键词
hepatic stellate cells; liver fibrosis; trichostatin A; extracellular matrix; proliferation;
D O I
暂无
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Eukaryotic gene expression has mainly been studied in the context of trans-acting transcription factors and their interaction with regulatory cis-elements. Evidence is accumulating, that the higher order structure of chromatin also plays an essential role in eukaryotic gene expression. Hepatic stellate cells are the major cellular source of extracellular matrix synthesis in chronic liver diseases leading to fibrosis. We explored the antifibrogenic effect of the histone deacetylase inhibitor trichostatin A (TSA) on hepatic stellate cells in vitro. Primary hepatic stellate cells as well as activated, subcultured stellate cells were exposed to 10(-7) M - 10(-9) M TSA. Collagens type I and III, and smooth muscle alpha -actin (alpha -SMA), a marker for transdifferentiation, were investigated at the protein and mRNA level by performing Northern hybridisation and quantitative immunoprecipitation. The antiproliferative effect was examined by IH-thymidine incorporation and cell counting. Hyperacetylation of histone H4 was demonstrated by acid urea Triton-X-100 (AUT) polyacrylamide gel electrophoresis. TSA at 10(-7) M retarded the morphological changes characteristic for activation of primary stellate cells. Synthesis of collagens type I and III, and alpha -SMA was strongly inhibited at both protein and mRNA level. The proliferation rate of primary hepatic stellate cells was strongly suppressed by 10(-7) M TSA. Hyperacetylation of histone H4 showed to be maximal at 10(-7) M TSA. Primary hepatic stellate cells were more affected by TSA than subcultured stellate cells.
引用
收藏
页码:239 / 246
页数:8
相关论文
共 50 条
  • [1] Mechanism of action of the antifibrogenic compound gliotoxin in rat liver cells
    Orr, JG
    Leel, V
    Cameron, GA
    Marek, CJ
    Haughton, EL
    Elrick, LJ
    Trim, JE
    Hawksworth, GM
    Halestrap, AP
    Wright, MC
    [J]. HEPATOLOGY, 2004, 40 (01) : 232 - 242
  • [2] R75761, a lead compound for the development of antiviral drugs in late stage poliomyelitis eradication strategies and beyond
    Thys, Bert
    De Palma, Armando M.
    Neyts, Johan
    Andries, Koen
    Vrijsen, Raf
    Rombaut, Bart
    [J]. ANTIVIRAL RESEARCH, 2008, 78 (03) : 278 - 281
  • [3] Role of the development scientist in compound lead selection and optimization
    Venkatesh, S
    Lipper, RA
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 2000, 89 (02) : 145 - 154
  • [4] A new lead compound for the development of Carbonic Anhydrase inhibitors
    Di Fiore, Anna
    De Simone, Giuseppina
    Vergara, Alessandro
    Caterino, Marco
    Alterio, Vincenzo
    Monti, Simona M.
    Ombouma, Joanna
    Dumy, Pascal
    Supuran, Claudiu T.
    Winum, Jean-Yves
    [J]. PROTEIN SCIENCE, 2015, 24 : 50 - 50
  • [5] A lead compound for the development of ABA 8′-hydroxylase inhibitors
    Ueno, K
    Yoneyama, H
    Saito, S
    Mizutani, M
    Sakata, K
    Hirai, N
    Todoroki, Y
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2005, 15 (23) : 5226 - 5229
  • [6] Studies on the targeted delivery of the antifibrogenic compound mycophenolic acid to the hepatic stellate cell
    Greupink, R
    Bakker, HI
    Reker-Smit, C
    van Loenen-Weemaes, AM
    Kok, RJ
    Meijer, DKF
    Beljaars, L
    Poelstra, K
    [J]. JOURNAL OF HEPATOLOGY, 2005, 43 (05) : 884 - 892
  • [7] A novel methylthio metabolite of s-triazolo[3,4-a]phthalazine, a lead compound for the development of antianxiety drugs, in rats
    Imamura, Y
    Noda, A
    Imamura, T
    Ono, Y
    Okawara, T
    Noda, H
    [J]. LIFE SCIENCES, 2003, 74 (01) : 29 - 36
  • [8] An Overview of Dihydroartemisinin as a Promising Lead Compound for Development of Anticancer Agents
    Olatunde, Olagoke Zacchaeus
    Yong, Jianping
    Lu, Canzhong
    [J]. MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2023, 23 (03) : 265 - 289
  • [9] Cyclodepsipeptides - Potential Drugs and Lead Compounds in the Drug Development Process
    Lemmens-Gruber, R.
    Kamyar, M. R.
    Dornetshuber, R.
    [J]. CURRENT MEDICINAL CHEMISTRY, 2009, 16 (09) : 1122 - 1137
  • [10] Ephedrine as a lead compound for the development of new DPP-IV inhibitors
    Jose Ojeda-Montes, Maria
    Ardid-Ruiz, Andrea
    Tomas-Hernandez, Sarah
    Gimeno, Aleix
    Cereto-Massague, Adria
    Beltran-Debon, Raul
    Mulero, Miquel
    Garcia-Vallve, Santiago
    Pujadas, Gerard
    Valls, Cristina
    [J]. FUTURE MEDICINAL CHEMISTRY, 2017, 9 (18) : 2129 - 2146